Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA

BACKGROUND: Targeted therapies (TKI) have improved the prognosis of ALK-rearranged lung cancer (ALK(+) NSCLC), but clinical courses vary widely. Early identification and molecular characterisation of treatment failure have key importance for subsequent therapies. We performed copy number variation (...

Descripción completa

Detalles Bibliográficos
Autores principales: Dietz, Steffen, Christopoulos, Petros, Yuan, Zhao, Angeles, Arlou Kristina, Gu, Lisa, Volckmar, Anna-Lena, Ogrodnik, Simon J., Janke, Florian, Fratte, Chiara Dalle, Zemojtel, Tomasz, Schneider, Marc A., Kazdal, Daniel, Endris, Volker, Meister, Michael, Muley, Thomas, Cecchin, Erika, Reck, Martin, Schlesner, Matthias, Thomas, Michael, Stenzinger, Albrecht, Sültmann, Holger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670098/
https://www.ncbi.nlm.nih.gov/pubmed/33161228
http://dx.doi.org/10.1016/j.ebiom.2020.103103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670098/
https://www.ncbi.nlm.nih.gov/pubmed/33161228
http://dx.doi.org/10.1016/j.ebiom.2020.103103

Ejemplares similares